NCT00712322 - A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 7, 2008

Primary Completion Date

May 23, 2013

Study Completion Date

May 23, 2013

Conditions

Neurogenic Detrusor Overactivity

Interventions

DRUG

Darifenacin

Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.

Trial Locations (12)

Pediatric Urology Associates PC, Tarrytown

Pediatric Urology Associates, PC, Lake Success

Pediatric & Adolescent Urology, Inc Akron Children's Hospital, Akron

Cincinnati Children's Hospital Medical Center, Cincinnati

Washington University Pediatric Urology, St Louis

University of California at San Diego, San Diego

Oregon Health & Science University, Portland

Children's Hospital, Karp 8210, Boston

Children's Hospital of Michigan, Detroit

Fundacion Hospital Infantil, Universitario De San Jose, Bogotá

Hospital Pablo Tobon Uribe, Medellín

Fundación Valle de Lili, Santiago de Cali